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Background. Neuromuscular blockade is 
associated with improved airway condi-
tions for intubation and superior condi-
tions for surgical interventions (predomi-
nantly important in laparoscopic surgery). 
Residual neuromuscular blockade in the 
postoperative period is, according to re-
cently published data, associated with a 
negative impact on perioperative morbid-
ity and mortality. 
Aim. The aim of the study was to describe 
daily practice in clinical paediatric anaes-
thesia in a tertiary children’s hospital. 
Methods. Data from anaesthesiology 
records during the period 1.1.2016 to 
31.12.2016 were retrospectively screened. 
Primary outcomes included the rate of 
surgery cases with neuromuscular block-
ade, the incidence of cases with periop-
erative neuromuscular blockade monitor-
ing and the incidence of neuromuscular 
pharmacologic block reversal. Secondary 
outcomes were myorelaxant usage accord-
ing to the age of patients and duration of 
surgery.    
Results. Overall 8046 paediatric patients 
underwent general anaesthesia in the study 
period. Muscle relaxants were adminis-
tered in 1650 cases (20.5%). The most fre-
quently administered muscle relaxant was 
mivacurium (48.2 %, n=795), followed by 
cis-atracurium (36.4 %, n=601), suxame-
thonium (10.3 %, n=170) and rocuronium 
(7.0 %, n=115). Neuromuscular blockade 
monitoring was used only in 2.5% (n=41) 
of cases. Active neuromuscular blockade 
reversal was administered in 5.8% (n=95) 
of cases.
Conclusion. Neuromuscular blockade in 
paediatric anaesthesia was less frequent 
compared to adults. The low rate of neuro-
muscular blockade monitoring in combi-
nation with the low rate of active block re-
versal can be considered dangerous due to 
the relatively high risk of potential residual 
postoperative blockade, that can negatively 
influence clinical outcome. 
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INTRODUCTION
Neuromuscular blockade (NB) can be 
considered a standard part of general an-
aesthesia. NB is associated with improved 
intubation conditions, reduced airway-
associated complications (1) and has led to 
development of special surgery techniques, 
including laparoscopy (NB improved sur-
gical conditions). (2) Recommended dos-
ing of muscle relaxants can be considered 
as only informative, according to the high 
variable duration of effect. (3) At the end 
of surgery, it is highly advisable to objec-
tively measure the neuromuscular block-
ade to exclude potential residual blockade 
(RB). Complete recovery is a mandatory 
requirement for safe anaesthesiology prac-
tice. RB in the postoperative period re-
mains a widely debated problem of daily 
practice in anaesthesiology, although very 
trivialized in the paediatric subpopulation. 
There is a strong and clear connection 
between RB and the negative impact on 
mortality and morbidity in postoperative 
period (regurgitation, silent aspiration, 
hypoxia, upper airway obstruction, pneu-
monia and patient discomfort) (4) and, if 
not treated, can lead to fatal consequences. 
Clinical signs of recovery (squeezing of the 
hand, lifting the head and other signs) are 
not sufficiently sensitive compared to ac-
celerometry (5) and require the patient´s 
active involvement, which can be difficult 
and is influenced by the age of the patient. 
Although, it seems, that the usage of NB 
in paediatric anaesthesia is lower (com-
pared to adults), the incidence of active 
pharmacological reversal of blockade and 
the incidence of neuromuscular blockade 
monitoring remains unclear. The aim of 
this study was to describe the actual prac-
tice in a tertiary paediatric anaesthesiology 
centre – incidence of NB usage, incidence 
of monitoring the depth of blockade and 
possible RB at the end of surgery and in-
cidence of active pharmacological reversal. 
 
MATERIALS AND METHODS 
The retrospective cohort study was ap-
proved by the local Ethics Committee of the 
University Hospital Brno and the trial was 
registered on www.clinicaltrials.gov (Clin-
icalTrials.gov Identifier: NCT03086915). 
All paediatric patients who underwent 
general anaesthesia at the Department of 
Paediatric Anaesthesiology and Intensive 
Care Medicine during the study period be-
tween 1. 1. 2016 and 1. 12. 2016, based on 
data derived from anaesthesiology records, 
were screened. Anaesthesiology cases with 
muscle relaxant usage were included in the 
analysis. Methods of descriptive statistics 
(incidence, mean, median) were used for 
SIGNA VITAE 2018; 14(1): 59-62
60   |  SIGNA VITAE
study group data (tables 1-4). The pri-
mary outcome was the frequency of neu-
romuscular blockade monitoring and the 
incidence of active pharmacological block 
reversal at the end of the operation. The 
secondary outcome was the frequency of 
different muscle relaxant usage according 
to the age of the patients and duration of 
surgery. Kruskal-Wallis H test was used to 
analyse the statistical significance by using 
the median values and Chi-squared test by 
using the average values (tables 2, 3). Pear-
son Chi-squared test was used to analyse 
the differences between types of surgery 
and patients with active block reversal (ta-
ble 4). Software SPSS 23 (IBM, USA) was 
used for statistical analysis.      
 
RESULTS
After initial screening, 8 046 paediatric 
patients underwent surgery under general 
anaesthesia in the study period. The rate of 
cases with NB was 20.9% (n=1 685). After 
exclusion of 17 (0.2%) patients due to in-
sufficient anaesthesiology records and 18 
(0.2%) due to age limit (age over 19 years), 
1 650 (20.5%) patients were included in 
the analysis. The median age of the cohort 
was 11 years (1 day – 19 years). The demo-
graphic data are summarized in the table 1. 
Neuromuscular blockade monitoring (ac-
celerometry, TOF-Watch SX) was used 
in 2.5% (n=41) of cases. From the whole 
cohort (n=1650), active pharmacological 
reversal of the blockade was administered 
in 5.8% (n=95) of cases. The drug used for 
block reversal was neostigmine in 71.6% 
(n=68) and sugammadex in 28.4% (n=27) 
of cases with active block reversal. The du-
ration of surgery was comparable between 
groups with neostigmine reversal, sugam-
madex reversal or non-reversal (median 
duration - 70 min vs. 70 min vs. 70 min, 
p=0.4096). Neuromuscular blockade was 
significantly more frequently antagonized 
in older patients (median age in years – 13 
vs. 14 vs. 10, p= p<0.001) (for detailed de-
scription see table 2). In 16 cases (23.5%), 
neostigmine was administered without at-
ropine (anticholinergic drug given to sup-
press the negative cholinergic stimulation 
induced by neostigmine), the only intrave-
nous anticholinergic agent available in the 
Czech Republic. The most frequently ad-
ministered MR was mivacurium (48.2%), 
followed by cis-atracurium (36.4%) and 
suxamethonium (10.3%). Neuromuscular 
blockade was most frequently antagonized 
after rocuronium administration (32 pa-
tients of 115 – 27.8%). The longest mean 
surgery duration time was in patients in 
the cis-atracurium subgroup (116 minutes, 
15-380 minutes, p<0.001) followed by the 
rocuronium subgroup of patients (94 min-
utes, 25-315 minutes, p<0.001) and the 
shortest mean surgery duration time was 
detected in atracurium subgroup (66 min-
utes, 30-150 minutes, p<0.001) followed by 
mivacurium subgroup (70 minutes, 10-655 
minutes, p<0.001) (table 3). 
The patients in our cohort were predomi-
nantly general surgical patients (42.0%, 
n=693), ENT patients (26.9%, n=445) and 
orthopaedic patients (14.7%, n=242). Ac-
cording to the type of surgical interven-
tion, active reversal was most frequently 
administered in the subgroup of general 
surgery patients (8.2%, n=57), which rep-
resents 60.0 % of all patients with active 
block reversal. The highest rate of rever-
sal was detected in the laparoscopic sur-
gery subgroup (active reversal rate 21.1% 
(39/185, p<0.001) (table 4). 
 
DISCUSSION
The most important finding was a low rate 
of neuromuscular blockade monitoring 
(2.5%). It can be considered very low when 
compared to data from the adult popu-
lation, where the reported rate is up to 
24.4%. (6) Due to the high risk of RB in the 
postoperative period in adults and the pae-
diatric population too, (7,8) the absence 
of monitoring with the combination of a 
low rate of active block reversal (5.8% in 
the study) can be considered risky. Neuro-
muscular blockade monitoring implemen-
tation in daily practice (from 2% to 60% of 
cases) has led (in the adult population) to a 
rapid increase in active block reversal fre-
quency (from 6% to 42%). (9,10) The low 
documented rate of blockade monitoring 
can be partially explained by the design 
of anaesthesiology records (no prede-
fined section for TOF measurement) and 
the low number of TOF-Watch monitors 
available on the anaesthesiology depart-
ment (at the study period only 2 monitors 
were available). The blockade induced by 
mivacurium was antagonized in 8 cases 
(1.0% of mivacurium group) – in all cases 
with neostigmine, although neostigmine 
can inhibit plasma cholinesterase and by 
doing so slow down mivacurium metabo-
lism in the plasma. (11) According to the 
manufacturer, the effect of mivacurium 
lasts for 13-23 minutes. Due to its unique 
metabolism (by plasma cholinesterase) 
there can be a higher risk of blockade pro-
longation and residual blockade in patients 
with liver dysfunction, kidney dysfunction 
and in elderly patients. The highest risk of 
prolonged blockade is in patients with the 
mutation of the gene for plasma cholinest-
erase, where in heterozygous individuals 
(prevalence in the population 1-3/1000) it 
can be prolonged by 50% and even more 
significantly in homozygous individuals. 
(12,13) Neuromuscular blockade monitor-
ing is therefore meaningful also in cases 
where short- or intermediate-acting mus-
cle relaxants have been used, because early 
recognition and RB reversal can positively 
influence the overall outcome. Patients 
extubated at the end of surgery with RB, 
defined as TOFr<0.9, have higher docu-
mented postoperative morbidity and mor-
tality. Implementing monitoring of neuro-
muscular blockade into routine practice 
can lead to early recognition of patients at 
risk and subsequently select patients who 
Table 1.  Age, weight and duration of surgery in patients with muscle relaxation
Weight (in kg) Age (in years) Surgery duration (in minutes)
Average 39.2 (0.8-121) 10.0 (0 -19) 88.0 (10-655)
Median 36.3 11 70
Table 2.  Age, duration of surgery in patients with active blockade reversal and in patients 
without active reversal
Neostigmine Sugammadex Without active reversal p value
Number of patients 68 (4.1%) 27 (1.6%) 1555 (94.2%) -
Age (in years) average 12.8 (1-19) 13.6 (6-19) 9.8 (0-19) p<0.001
Age (in years)
median 
13 14 10 p<0.001
Surgery duration 
(in minutes) average
84.7 (30-300) 82.3 (25-170) 87.9 (10-655) p=0.9744
Surgery duration (in 
minutes) median 
70 70 70 p=0.4096
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benefit the most from active block reversal. 
Currently there are two drugs designated 
for neuromuscular blockade reversal: ne-
ostigmine (Syntostigmin®) and sugamma-
dex (Bridion®). Sugammadex is a specific 
gama-cyklodextrine, that acts through en-
capsulation of the free plasmatic fraction 
of aminosteroids (rocuronium, vecuro-
nium). According to the manufacturer, it is 
currently approved for use in patients over 
2 years of age. The dosage depends on the 
depth of the RB (2mg/kg if TOF 1-2, 4mg 
if PTC – post-tetanic count 1-2). Only sug-
ammadex is capable of fully reversing deep 
neuromuscular blockade, in the case of a 
failed airway (dose needed for complete 
reversal – 16mg/kg). This technique is not 
recommended in paediatric patients due 
to lack of data, however it can be lifesav-
ing in an urgent situation. Neostigmine, as 
the second drug of choice for block rever-
sal, acts as a reversible inhibitor of acetyl-
cholinesterase and reinforces the effect of 
acetylcholine on nicotinic and muscarinic 
receptors. Due to the mechanism of the 
drug, neostigmine administration, with-
out anticholinergic medication (atropine) 
co-administration, can be considered dan-
gerous. The main neostigmine limitation is 
that it has the capability of reversing only 
shallow blockade (TOF 1-2) but it acts on 
both – aminosteroids (rocuronium, vecu-
ronium) and bensylisoquinolines (atracu-
rium, cis-atracurium). However, the effect 
has a slow onset and a ceiling effect. Ne-
ostigmine administration to patients with 
a deep blockade (TOF 1) can lead to para-
doxical deepening of the blockade. The low 
rate of neuromuscular blockade monitor-
ing at the end of surgery may have been 
influenced by the retrospective design of 
the study and insufficient documentation. 
These results point to the several clini-
cal problems – neuromuscular blockade 
reversal with neostigmine without an an-
ticholinergic agent, active reversal of neu-
romuscular blockade induced by mivacu-
rium with neostigmine and the low rate of 
neuromuscular blockade. 
CONCLUSION
The low incidence of active block reversal 
can be considered dangerous, due to the 
high risk of RB. (7,9,14) It is highly recom-
mended to monitor the depth of neuro-
muscular blockade in all patients in whom 
muscle relaxants have been administered, 
in agreement with a recently published na-
tional statement for safe anaesthesia prac-
tice by Czech Society of Anaesthesiology 
and Intensive Care Medicine (published 
on 8th April 2017).    
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Table 4. Neuromuscular blockade reversal according to the type of surgery




























5.2% (n=86) 1.7% (n=28)
Number of patients 
with active reversal 
















3.4% (n=3) 0.0% (n=0)
Table 3. Block reversal, duration of surgery and age according to muscle relaxant
Mivacurium Cis-atracurium Rocuronium Suxamethonium Atracurium p value 
Number of patients 795 (48.2%) 601 (36.4%) 115 (7.0 %) 170 (10.3%) 18 (1.1%) p<0.001
Number of patients with 
block reversal 
8 (1.0%) 53 (8.8%) 32 (27.8%) 0 (0%) 2 (11.1%) p<0.001
Age (in years) average 10.4 (0-19) 9.8 (0-19) 11.3 (0-19) 7.2   (0-19) 12.2 (0-17) -
Age (in years)
median 
11 11 12 6 13.5 -














Surgery duration (in 
minutes)
median 
60 105 80 60 60 p<0.001
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